Press Release: European Medicines Agency recommends restricting Trobalt to last-line therapy in partial epilepsy

Author (Corporate)
Series Title
Series Details EMA/321395/2013 (30.05.13)
Publication Date 30/05/2013
Content Type

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), in May 2013, recommended restricting the use of the anti-epileptic medicine Trobalt (retigabine) only to those patients for whom other anti-epileptic medicines had proved inadequate or had not been tolerated. This followed a careful evaluation of cases of pigmentation (abnormal colouring) of the skin, nails, lips and eye tissues, including the retina (the light sensitive layer at the back of the eye) reported in patients taking part in long-term studies.
Source Link http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/05/news_detail_001802.jsp&mid=WC0b01ac058004d5c1
Related Links
EMA: Press Release: EMA/321395/2013 (30.05.13): European Medicines Agency recommends restricting Trobalt to last-line therapy in partial epilepsy http://www.emea.europa.eu/docs/en_GB/document_library/Press_release/human/001245/WC500143799.pdf
Subject Categories
Countries / Regions